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Sirs: In 1996, a new variant of
Creutzfeldt-Jakob disease (vCJD)
linked to the cattle bovine spong-
iform encephalopathy (BSE) epi-
demic was described in the United
Kingdom (UK) [8, 2]. Up until
now, 191 cases have been reported
worldwide. Most of these cases
have occurred in the UK (159), but
in recent years vCJD has been
identiﬁed in a number European
countries with indigenous out-
breaks of BSE, including 18 cases
in France, four in Ireland, two in
the Netherlands and single cases
in Portugal, Italy and Spain.
However, a growing number of
cases of vCJD have also been
identiﬁed in countries outside
Europe including Japan (n = 1),
the United States (n = 2) and
Canada (n = 1) and also in Saudi
Arabia (n = 1), in which BSE has
not been identiﬁed. A number of
the non-UK cases, including two
Irish, the Canadian, the two US
cases, and possibly the Japanese
case, may well have been infected
during periods of residence in the
UK, but the majority of cases
(n = 25) occurring outside the
UK, like the two cases that devel-
oped in the Netherlands, had
never visited the UK [1]. In this
study we describe the ﬁrst patient
identiﬁed with vCJD in the Neth-
erlands [3].
The patient was a 26-year-old
woman with previous medical
history of two abortions in 1996
and in 1998 and a psychiatric
history of anxiety and a phobic
disorder since 1999. However, one
year previous to the vCJD disease
onset, she had completely recov-
ered from her psychiatric prob-
lems and was able to function
normally. She worked in a catering
and food-processing business for
6 years, from 1998 to the disease
onset. She consumed all types of
meat frequently, including raw
meat, and particularly processed
meat products. She had no history
of neurosurgical procedures, hor-
monal treatments, or tissue or
organ grafts, and she had never
received or donated blood. She
never traveled to the UK. She had
no family history of dementia or
any other neurodegenerative dis-
order.
From November 2003, the pa-
tient developed new psychiatric
symptoms, particularly anxiety
and aggressive behavior. In spring
2004, the family also noticed some
forgetfulness. A few months later,
the psychiatric symptoms wors-
ened. She suffered from panic
attacks, became very dependent
and apathetic, and showed
regressive behavior. She also had
visual hallucinations in which she
saw animals. In July 2004, two
weeks after a dental extraction, she
started complaining of severe fa-
cial pain in her upper jaw. Her
dentist examined her but no
organic cause was found. At that
point she was seen by a psychia-
trist who suspected that she was
suffering from anxiety and a con-
version disorder.
In September 2004, the patient
developed involuntary movements
of her right foot, with dystonic
eversion-inversion posturing and
occasionally some jerking move-
ments. She also developed pares-
thesiae in the lower limbs and gait
difﬁculties, especially when walk-
ing in the dark. In November, the
family also noticed dysarthria and
problems in the motor coordina-
tion of the upper limbs. She had
several episodes of blurring of
vision. During this period, she was
twice hospitalized in a psychiatric
ward because of increasing anxi-
ety, regressive behavior and facial
pain.
From January to March 2005
the involuntary movements wors-
ened signiﬁcantly, accompanied
by generalized stiffness, now
involving all extremities. In March
the patient was again hospitalized
in a psychiatric ward with the
clinical diagnosis of a conversion
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operidol was started. Two days
later she suffered a tonic-clonic
seizure followed by hyperthermia
that required admission to an
intensive care department. No
cause was found for the persistent
high temperature, and the neuro-
leptic medication was withdrawn.
The patient was treated for malig-
nant neuroleptic syndrome with-
out success. The neurological state
of the patient worsened rapidly.
On neurological examination
she was mute, opened her eyes to
verbal stimuli but there was no
visual ﬁxation. She had variable
extrapyramidal rigidity in the
extremities with dystonic move-
ments of the hands and feet, and
she had a positive Babinski sign in
her right foot. Routine laboratory
examinations only revealed mild
increases of the aspartate amino-
transpherase (ASAT) and creatine
phosphokinase (CPK), which later
normalized. The cerebrospinal
ﬂuid was normal, and 14-3-3 pro-
tein was not detectable. Tau pro-
tein determination in CSF was
performed after the referral of the
patient to the CJD registry, and it
showed abnormally high levels
(1314 ng/l). The electroencepha-
logram showed generalized slow-
ing, more evident in the left
hemisphere, but without any
periodic complexes. Brain MRI
showed symmetrical hyperinten-
sities in the pulvinar and the
dorsomedial nuclei of the thalami
on T2- and ﬂuid-attenuated inver-
sion recovery (FLAIR)-weighted
images (Figure 1). Genotyping of
the prion protein gene (PRNP)
identiﬁed no mutation and
homozygosity for methionine at
codon 129.
Following the current WHO
criteria, the patient was diagnosed
in life with probable vCJD based
on the clinical features, laboratory
ﬁndings, brain MRI ﬁndings and
PRNP genotyping [7]. In May 2005
the patient died, and the diagnosis
was conﬁrmed by post mortem
neuropathological examination of
the brain, which showed typical
features of vCJD, including ﬂorid
plaques (Figure 2). Western blot
analysis of unﬁxed brain tissue
showed a characteristic type 2B
PrP
Sc isoform (Figure 3).
Non-UK cases of vCJD may
potentially have been infected
during a period of residence in the
UK in the 1980s and early 1990s
(for example the US and Canadian
cases). Our patient had never
traveled to the UK, but may have
been exposed through either
indigenous BSE infected animals
or BSE infected exports from the
UK to the Netherlands during the
1980s and early 1990s. Thus far, all
non-UK cases of vCJD who had
Fig. 1 FLAIR-weighted images of the brain MRI
study, showing bilateral symmetrical regions of
hyperintensity in the pulvinar and the dorsomedial
nuclei of the thalami (‘‘hockey stick sign’’)
Fig. 2 Neuropathology of variant CJD: A. florid
plaque surrounded by small areas of spongiform
change in the occipital cortex (Luxol-PAS stain).
B. Multiple small cluster plaques in the occipital
cortex (Luxol-PAS stain). C. kuru-type plaque in the
cerebellar cortex (Luxol-PAS stain).
D. Immunohistochemistry for prion protein (using
monoclonal antibody 3F4) shows strong staining of
plaques in the occipital cortex, along with amorphous
and pericellular deposits
959never previously visited the UK
show disease characteristics anal-
ogous to the UK cases. The clinical
features, PRNP codon 129 geno-
type, neuropathological ﬁndings
and western blot PrP
Sc isoform of
our patient are indistinguishable
from the United Kingdom vCJD
cases, pointing towards a common
etiological agent.
The Netherlands CJD surveil-
lance system is part the EUROCJD
group, a EU-funded network
established in 1993 with the aim of
monitoring the disease incidence
and detecting new vCJD cases [5].
In the Netherlands, only 80 BSE
cases have been reported [4]. The
ﬁrst case of variant CJD diagnosed
in the Netherlands highlights the
importance of continuing multi-
national surveillance of human
prion diseases, even in countries
with a low BSE incidence, during
the preparation of this manuscript
a second probable vCJD case has
beenascertainedinourcountry[6].
The early detection of vCJD
patientsiscrucialastherearemajor
public health implications, includ-
ing of tracing of blood products
from patients who were blood
donors and tracing of surgical
instruments, in this case dental
instruments. Despite of a long
disease course (18 months) the
diagnosis in this patient was par-
ticularly difﬁcult owing to the past
psychiatric history. The brain MRI
ﬁndings played a crucial role in the
diagnosis by the treating neurolo-
gist (J.I.H.). This triggered the
notiﬁcation to the CJD registry in
Rotterdam.
Thiscasereportunderscoresthe
valueofthe MRIinthe diagnosisof
vCJD and the need for an increased
awareness of radiologists and neu-
rologists of the MRI ﬁndings in
vCJD, including in countries with a
low incidence of BSE.
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Fig. 3 Western blot analysis of protease-resistant
prion protein in this patient (Case) shows an
identical pattern of glycosylation and size of the
unglycosylated fragment (lowest band ~ 19Kd) to
a control case of vCJD (Type 2B), which is markedly
different from a case of sporadic CJD (Type 1).
(Reproduced with permission of Prof. Dr. A.J.P.M.
Overbeke editor of Ned Tijdschr Geneeskd [3])
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